Article: Vaginal yeasts in the era of "over the counter" antifungals

Objective: To establish whether there has been any rise in the prevalence of non-albicans Candida species isolated from vaginal swabs since the introduction of "over the counter" antifungal treatments.

Method: A retrospective review looking at all positive vaginal yeast isolates collected from women attending one genitourinary medicine clinic during the 6 year period from 1993 to 1998 inclusive. All positive vaginal yeast isolates were included, regardless of whether or not the patients were symptomatic. Isolates from HIV positive women were excluded from the analysis.

Results: No increase in non-albicans vaginal yeast isolates was shown during the period studied. The proportion of non-albicans yeasts remained constant at approximately 5% of the total yeasts isolated. The most common non-albicans yeast isolated was C glabrata.

Conclusion: There is no evidence from this study to suggest that the increasing use of "over the counter" antifungal treatment has selected for atypical, possibly inherently azole resistant, strains of vaginal yeasts in HIV seronegative women.

Citing Articles

Vulvovaginal Candidosis (Excluding Mucocutaneous Candidosis): Guideline of the German (DGGG), Austrian (OEGGG) and Swiss (SGGG) Society of Gynecology and Obstetrics (S2k-Level, AWMF Registry Number 015/072, September 2020).

Farr A, Effendy I, Tirri B, Hof H, Mayser P, Petricevic L Geburtshilfe Frauenheilkd. 2021; 81(4):398-421.

PMID: 33867561 PMC: 8046514. DOI: 10.1055/a-1345-8793.

Guideline: Vulvovaginal candidosis (AWMF 015/072, level S2k).

Farr A, Effendy I, Tirri B, Hof H, Mayser P, Petricevic L Mycoses. 2021; 64(6):583-602.

PMID: 33529414 PMC: 8248160. DOI: 10.1111/myc.13248.

Species distribution and susceptibility profiles of Candida species isolated from vulvovaginal candidiasis, emergence of C. lusitaniae.

Hashemi S, Shokohi T, Abastabar M, Aslani N, Ghadamzadeh M, Haghani I Curr Med Mycol. 2020; 5(4):26-34.

PMID: 32104741 PMC: 7034787. DOI: 10.18502/cmm.5.4.2062.

Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013).

Mendling W, Friese K, Mylonas I, Weissenbacher E, Brasch J, Schaller M Geburtshilfe Frauenheilkd. 2016; 75(4):342-354.

PMID: 27065484 PMC: 4813053. DOI: 10.1055/s-0035-1545741.

Highly-cited estimates of the cumulative incidence and recurrence of vulvovaginal candidiasis are inadequately documented.

Rathod S, Buffler P BMC Womens Health. 2014; 14(1):43.

PMID: 24612727 PMC: 3975582. DOI: 10.1186/1472-6874-14-43.

References

1.

Denning D, Baily G, Hood S . Azole resistance in Candida. Eur J Clin Microbiol Infect Dis. 1997; 16(4):261-80. DOI: 10.1007/BF01695630. View

2.

Sobel J . Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 1985; 152(7 Pt 2):924-35. DOI: 10.1016/s0002-9378(85)80003-x. View

3.

Sobel J . Vaginal infections in adult women. Med Clin North Am. 1990; 74(6):1573-602. DOI: 10.1016/s0025-7125(16)30496-5. View

4.

Price M, Larocco M, Gentry L . Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother. 1994; 38(6):1422-4. PMC: 188224. DOI: 10.1128/AAC.38.6.1422. View

5.

Spinillo A, Capuzzo E, Gulminetti R, Marone P, Colonna L, Piazzi G . Prevalence of and risk factors for fungal vaginitis caused by non-albicans species. Am J Obstet Gynecol. 1997; 176(1 Pt 1):138-41. DOI: 10.1016/s0002-9378(97)80026-9. View

Vaginal Yeasts in the Era of "over the Counter" Antifungals